Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
- PMID: 14679293
- DOI: 10.1093/rheumatology/keh058
Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
Abstract
Objectives: To investigate proinflammatory cytokine expression in temporal arteries from patients with giant-cell arteritis (GCA) and to analyse its relationship with the intensity of the initial systemic inflammatory reaction and response to corticosteroid therapy.
Methods: Quantification of interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), and interleukin-6 (IL-6) mRNA by real-time quantitative PCR in temporal artery samples from 36 patients with biopsy-proven GCA and 11 controls. Immunohistochemical detection of IL-1beta, TNFalpha, and IL-6 in temporal artery sections from 74 patients with GCA and 15 controls. Clinical and biochemical parameters of inflammation as well as the time (weeks) required to reach a maintenance prednisone dose <10 mg/day were recorded.
Results: IL-1beta (13.8 +/- 2.5 vs 5.4 +/- 1.3 relative units, P = 0.012) and IL-6 transcripts (34 +/- 13.7 vs 7.8 +/- 4.5 relative units, P = 0.034) were significantly more abundant in patients with a strong systemic inflammatory response compared with those with no inflammatory parameters. Immunohistochemical scores for IL-1beta (2.7 +/- 0.3 vs 1.9 +/- 0.2, P = 0.018), TNFalpha (3.2 +/- 0.2 vs 2.4 +/- 0.3, P = 0.028) and IL-6 (3 +/- 0.2 vs 2.1 +/- 0.3, P = 0.023) were also significantly higher in patients with strong systemic inflammatory reaction. A significant correlation was found between the amount of tissue TNFalpha mRNA and the time required to reach a maintenance dose of prednisone <10 mg/day (r = 0.586, P = 0.001).
Conclusion: GCA patients with a strong systemic inflammatory response, who have been previously shown to be more resistant to corticosteroid therapy, have elevated tissue expression of proinflammatory cytokines IL-1beta, TNFalpha and IL-6. High production of TNFalpha is associated with longer corticosteroid requirements.
Similar articles
-
Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.Circulation. 2003 May 20;107(19):2428-34. doi: 10.1161/01.CIR.0000066907.83923.32. Epub 2003 May 12. Circulation. 2003. PMID: 12742994 Clinical Trial.
-
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis.Rheumatology (Oxford). 2006 Nov;45(11):1356-63. doi: 10.1093/rheumatology/kel128. Epub 2006 Apr 18. Rheumatology (Oxford). 2006. PMID: 16621921
-
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.Ann Rheum Dis. 2013 Sep 1;72(9):1481-7. doi: 10.1136/annrheumdis-2012-201836. Epub 2012 Sep 19. Ann Rheum Dis. 2013. PMID: 22993227 Clinical Trial.
-
Pathogenesis of giant cell arteritis: More than just an inflammatory condition?Autoimmun Rev. 2010 Aug;9(10):635-45. doi: 10.1016/j.autrev.2010.05.002. Epub 2010 May 8. Autoimmun Rev. 2010. PMID: 20457278 Review.
-
[Horton's disease and corticosteroid-responsive hearing loss].Ann Med Interne (Paris). 2000 Nov;151(7):600-602. Ann Med Interne (Paris). 2000. PMID: 11139662 Review. French.
Cited by
-
Successful treatment of refractory giant cell arteritis with etanercept.Rheumatol Int. 2016 Aug;36(8):1177-9. doi: 10.1007/s00296-016-3521-4. Epub 2016 Jul 1. Rheumatol Int. 2016. PMID: 27368671 No abstract available.
-
Branched-chain amino acids supplementation induces insulin resistance and pro-inflammatory macrophage polarization via INFGR1/JAK1/STAT1 signal pathway.Mol Med. 2024 Sep 12;30(1):149. doi: 10.1186/s10020-024-00894-9. Mol Med. 2024. PMID: 39267003 Free PMC article.
-
A novel inhalable quercetin-alginate nanogel as a promising therapy for acute lung injury.J Nanobiotechnology. 2022 Jun 11;20(1):272. doi: 10.1186/s12951-022-01452-3. J Nanobiotechnology. 2022. PMID: 35690763 Free PMC article.
-
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.RMD Open. 2023 Jun;9(2):e003233. doi: 10.1136/rmdopen-2023-003233. RMD Open. 2023. PMID: 37349123 Free PMC article.
-
Endovascular Therapy for Intracranial Giant Cell Arteritis : Systematic Review, Technical Considerations and the Effect of Intra-arterial Calcium Channel Blockers.Clin Neuroradiol. 2022 Dec;32(4):1045-1056. doi: 10.1007/s00062-022-01171-0. Epub 2022 May 3. Clin Neuroradiol. 2022. PMID: 35503467 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical